Epidemiologic Relationships Between A1C and All-Cause Mortality During a Median 3.4-Year Follow-up of Glycemic Treatment in the ACCORD Trial
Open accessThe DOI matches its Crossref record; 20 of the 21 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Randomized treatment comparing an intensive glycemic treatment strategy with a standard strategy in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial was ended early because of an unexpected excess of mortality in the intensive arm. As part of ongoing post hoc analyses of potential mechanisms for this finding, we explored whether on-treatment A1C itself had an independent relationship with mortality. RESEARCH DESIGN AND METHODS: Participants with type 2 diabetes (n = 10,251 with mean age 62 years, median duration of diabetes 10 years, and median A1C 8.1%) were randomly assigned to treatment strategies targeting either A1C <6.0% (intensive) or A1C 7.0–7.9% (standard). Data obtained during 3.4 (median) years of follow-up before cessation of intensive treatment were analyzed using several multivariable models. RESULTS: Various characteristics of the participants and the study sites at baseline had significant associations with the risk of mortality. Before and after adjustment for these covariates, a higher average on-treatment A1C was a stronger predictor of mortality than the A1C for the last interval of follow-up or the decrease of A1C in the first year. Higher average A1C was associated with greater risk of death. The risk of death with the intensive strategy increased approximately linearly from 6–9% A1C and appeared to be greater with the intensive than with the standard strategy only when average A1C was >7%. CONCLUSIONS: These analyses implicate factors associated with persisting higher A1C levels, rather than low A1C per se, as likely contributors to the increased mortality risk associated with the intensive glycemic treatment strategy in ACCORD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The potential risks of intensive glycemic control may be obviated by incorporating agents that are not associated with hypoglycemia, especially in persons with frequent severe hypoglycemia, hypoglycemia unawareness, or a very long duration of DM, and particularly in the presence of established and advanced atherosclerosis, advanced age, and terminal illness.69,70,76–81”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [80]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“A corollary of this issue is the safety of those therapies in view of the demonstrated increase of frequency of severe hypoglycemia during attempts at intensive glycemic control.70,76,80,85,86”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [80]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“These trials have more or less uniformly demonstrated a benefit, with lifestyle more efficacious than all medications with the exception of the thiazolidinediones140–152.”
From Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future (2014) · cites this paper as [148]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Stratton, I. M. (2000) · BMJ · doi:10.1136/bmj.321.7258.405 · Cited by 9,059 · cited 1×
“This association, not taking into consideration the glycemic treatment strategy, is similar to the 12 and 14% increments of mortality associated with 1% higher average A1C in epidemiologic analyses from other studies (6,19).”
ResultEffects of Intensive Glucose Lowering in Type 2 Diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802743 · Cited by 7,888
Haffner, S. M., Lehto, S., Rönnemaa, T., Pyörälä, K., & Laakso, M. (1998) · New England Journal of Medicine · doi:10.1056/nejm199807233390404 · Cited by 7,000
Stamler, J., Vaccaro, O., Neaton, J. D., Wentworth, D., & The Multiple Risk Factor Intervention Trial Research Group (1993) · Diabetes Care · doi:10.2337/diacare.16.2.434 · Cited by 4,063
Flexible smoothing with B-splines and penalties
Eilers, P. H. C., & Marx, B. D. (1996) · Statistical Science · doi:10.1214/ss/1038425655 · Cited by 3,666 · cited 1×
“Curves modeling the relationships over the range of observed A1C values (penalized B-splines) (17,18) were used to explore the linearity assumption in the Cox proportional hazards model.”
MethodDiabetes and Cardiovascular Disease: The Framingham Study
Kannel, W. B. (1979) · JAMA · doi:10.1001/jama.1979.03290450033020 · Cited by 2,936
Coutinho, M., Gerstein, H. C., Wang, Y., & Yusuf, S. (1999) · Diabetes Care · doi:10.2337/diacare.22.2.233 · Cited by 1,685
Meta-analysis: glycosylated hemoglobin and cardiovascular disease in diabetes mellitus
Selvin, E., Marinopoulos, S., Berkenblit, G., Rami, T., Brancati, F. L., Powe, N. R., & Golden, S. H. (2004) · Annals of Internal Medicine · doi:10.7326/0003-4819-141-6-200409210-00007 · Cited by 1,657
Hurvich, C. M., Simonoff, J. S., & Tsai, C.-L. (1998) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/1467-9868.00125 · Cited by 1,241 · cited 1×
“Curves modeling the relationships over the range of observed A1C values (penalized B-splines) (17,18) were used to explore the linearity assumption in the Cox proportional hazards model.”
MethodSkyler, J. S., Bergenstal, R., Bonow, R. O., Buse, J., Deedwania, P., Gale, E. A. M., Howard, B. V., Kirkman, M. S., Kosiborod, M., Reaven, P., et al. (2009) · Diabetes Care · doi:10.2337/dc08-9026 · Cited by 881
Self-citation
Cited by
Items 201–300 of 404
Goldfine, A. B., Phua, E.-J., & Abrahamson, M. J. (2014) · Circulation · doi:10.1161/circulationaha.113.006634 · Cited by 16
“Although attempts to achieve near-normal glycemia were associated with increased mortality in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial, this has not been observed in other studies of intensive glycemic control.9 Factors associated with persistently higher HbA 1c levels despite inten- sive g…”
Complications of Diabetes Mellitus
Brownlee, M., Aiello, L. P., Cooper, M. E., Vinik, A. I., Nesto, R. W., & Boulton, A. J. M. (2011) · Elsevier eBooks · doi:10.1016/b978-1-4377-0324-5.00033-x · Cited by 22
Hypoglycemia in Type 2 Diabetes: Current Controversies and Changing Practices
Bloomgarden, Z. T., & EINHORN, D. F. (2012) · Frontiers in Endocrinology · doi:10.3389/fendo.2012.00066 · Cited by 15
“Furthermore, those in the intensive treatment group who failed to show at least a 0.5% reduction in A1c during the first year of the study had higher mortality, with higher mean on-trial A1c in this group associated with greater likelihood of mortality (Riddle et al., 2010).”
BackgroundInfluentialInsulin Resistance Correlates with the Arterial Stiffness before Glucose Intolerance
Fang, F., Liu, M., Cheng, X., Zhong, W., Miao, X., Li, J., Li, C., & Tian, H. (2014) · Internal Medicine · doi:10.2169/internalmedicine.53.0690 · Cited by 17
“The elevated plasma glucose level in diabetes or an impaired glucose tolerance is a risk factor for cardiovascular events and mortality (1-3).”
BackgroundAcculturation and Self-Management Perceptions Among Mexican American Adults With Type 2 Diabetes
Plasencia, J., Hoerr, S. L., Carolan, M., & Weatherspoon, L. (2017) · Family & Community Health · doi:10.1097/fch.0000000000000139 · Cited by 18
Glycemic control and cardiovascular mortality
Riddle, M. C. (2011) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0b013e3283446b7e · Cited by 19
Self-citationNon-linear actions of physiological agents: Finite disarrangements elicit fitness benefits
Sedlić, F., & Kovač, Z. (2017) · Redox Biology · doi:10.1016/j.redox.2017.05.008 · Cited by 16
Nusca, A., Bernardini, F., Mangiacapra, F., Maddaloni, E., Melfi, R., Ricottini, E., Piccirillo, F., Manfrini, S., Ussia, G. P., & Grigioni, F. (2021) · Journal of Diabetes Research · doi:10.1155/2021/4952447 · Cited by 18
“Notably, glycemic control significantly impacts the cardiovascular prognosis of diabetic patients [21, 38, 39].”
BackgroundSchwartz, A. V., Vittinghoff, E., Margolis, K. L., Scibora, L. M., Palermo, L., Ambrosius, W. T., Hue, T. F., & Ensrud, K. E. (2013) · Calcified Tissue International · doi:10.1007/s00223-013-9703-0 · Cited by 15
Self-citationIs HbA1c <7% a Marker of Poor Performance in Individuals >65 Years Old?
Bloomgarden, Z. T., EINHORN, D. F., & Handelsman, Y. (2017) · Diabetes Care · doi:10.2337/dci16-0043 · Cited by 16
“on-trial HbA1c levels were higher were the ones whose mortality rates increased (6).”
BackgroundWang, S., He, Y., Xu, L., Zhang, S., Gu, X., Gu, J., Shi, J., Shen, Y., & Tang, Z. (2018) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2018.01.021 · Cited by 16
Okin, P. M., Hille, D. A., Kjeldsen, S. E., Dahlöf, B., & Devereux, R. B. (2013) · Blood Pressure · doi:10.3109/08037051.2013.791414 · Cited by 14
Frier, B. M., Schernthaner, G., Heller, S. R., & Isease, D. (2011) · Cited by 14
Riddle, M. C., & Gerstein, H. C. (2015) · Diabetes Care · doi:10.2337/dc15-1073 · Cited by 15
Self-citationSystemic Therapies for Diabetic Retinopathy
Frank, R. N. (2014) · Ophthalmology · doi:10.1016/j.ophtha.2014.08.019 · Cited by 14
Bloomgarden, Z. (2013) · Journal of Diabetes · doi:10.1111/1753-0407.12065 · Cited by 13
Schwartz, S. S., Fabricatore, A. N., & Diamond, A. (2012) · Advances in experimental medicine and biology · doi:10.1007/978-1-4614-5441-0_31 · Cited by 17
Inzucchi, S. E., & Majumdar, S. K. (2014) · Medical Clinics of North America · doi:10.1016/j.mcna.2014.08.018 · Cited by 15
Durability of glycemic control using U-500 insulin
Dailey, A. M., Gibert, J. A., & Tannock, L. R. (2011) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2011.10.030 · Cited by 13
Intensive treatment of hyperglycaemia: ACCORD
Klein, R. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61028-8 · Cited by 13
Preventing Diabetic Retinopathy Progression
Ferris, F. L., & Nathan, D. M. (2016) · Ophthalmology · doi:10.1016/j.ophtha.2016.05.039 · Cited by 13
Tschöpe, D., Bramlage, P., Schneider, S., & Gitt, A. K. (2016) · Diabetes and Vascular Disease Research · doi:10.1177/1479164115610470 · Cited by 12
Szafranski, K., de Pouvourville, G., Greenberg, D., Harris, S. B., JENDLE, J. H., Shaw, J. E., Coaquira, J., Poon, Y., & Levrat‐Guillen, F. (2024) · Value in Health · doi:10.1016/j.jval.2024.01.010 · Cited by 16
for the ACCORD Group of Investigators, Punthakee, Z., Miller, M. E., Simmons, D. L., Riddle, M. C., Ismail‐Beigi, F., Brillon, D. J., Bergenstal, R. M., Savage, P. J., HRAMIAK, I. M., et al. (2014) · Diabetologia · doi:10.1007/s00125-014-3318-5 · Cited by 13
Self-citationAlemán, J. A., Prieto-Díaz, M. Á., Hernández, M. L., Galindo, S. B., Iserte, A. D. L. S., Claros, N. M., & Romanos, F. G. (2011) · Atención Primaria · doi:10.1016/j.aprim.2010.05.016 · Cited by 13
Hu, J., Hsu, H., Yuan, X., Lou, K., Hsue, C., Miller, J. D., Lu, J., Lee, Y., & Lou, Q. (2020) · Journal of Endocrinological Investigation · doi:10.1007/s40618-020-01410-6 · Cited by 15
“The Action to Control Cardiovascular Risk in Diabetes (ACCORD) study revealed that older patients with longer duration of type 2 diabetes experienced greater mortality risk with more rapid A1c reduction from baseline [25].”
BackgroundKuppinger, D., & Hartl, W. H. (2013) · Nutrition · doi:10.1016/j.nut.2012.11.019 · Cited by 13
Huang, R., Abdelmoneim, S. S., Nhola, L. F., Basu, R., Basu, A., & Mulvagh, S. L. (2015) · Expert Review of Cardiovascular Therapy · doi:10.1586/14779072.2015.1015992 · Cited by 14
Kehl, K. G., Findeisen, H. M., Fardo, D. W., Bruemmer, D., Mannino, D. M., & Sanderson, W. T. (2011) · European Journal of Endocrinology · doi:10.1530/eje-11-0171 · Cited by 12
Patoulias, D., Stavropoulos, K., Imprialos, K. P., Athyros, V. G., Doumas, M. N., & Karagiannis, A. I. (2019) · Current Vascular Pharmacology · doi:10.2174/1570161117666190426162746 · Cited by 13
Kim, Y. A., Lee, Y., & Seo, J. H. (2020) · Journal of Diabetes Research · doi:10.1155/2020/9806790 · Cited by 12
Optimizing glycemic control and minimizing the risk of hypoglycemia in patients with type 2 diabetes
Schwartz, S. J. (2013) · Drugs in Context · doi:10.7573/dic.212255 · Cited by 15
Shao, H., Lin, J., Zhuo, X., Rolka, D. B., Gregg, E. W., & Zhang, P. (2019) · Diabetes Care · doi:10.2337/dc19-0381 · Cited by 15
Niu, S., Alkhuzam, K. A., Guan, D., Jiao, T., Shi, L., Fonseca, V. A., Laiteerapong, N., Ali, M. K., Schatz, D., Guo, J. S., et al. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15332 · Cited by 11
Glycaemic control, cardiovascular disease, and mortality in type 2 diabetes
Chiasson, J., & LeLorier, J. (2014) · The Lancet · doi:10.1016/s0140-6736(14)60884-9 · Cited by 11
Overview of the Guidelines and Evidence for the Pharmacologic Management of Type 2 Diabetes Mellitus
Liday, C. (2011) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.31.12.37s · Cited by 11
Diabetes Control Among Hispanics in the Action to Control Cardiovascular Risk in Diabetes Trial
Getaneh, A., Light, L. S., Brillon, D. J., Escandón, J. C., Felicetta, J. V., Evans, G. W., Lopez-Jimenez, C., Cuddihy, R. M., & Bigger, J. T. (2012) · Journal of General Internal Medicine · doi:10.1007/s11606-012-2131-4 · Cited by 12
Self-citationAnyanwagu, U., Mamza, J., Donnelly, R., & IDRIS, I. R. (2017) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2945 · Cited by 11
“1) Third quintile 846 (22) 1,088 (21) 193 (21) 740 (20) 963 (22) 3,830 (20.”
Clinical practice and implications of recent diabetes trials
Webster, M. W. I. (2011) · Current Opinion in Cardiology · doi:10.1097/hco.0b013e328347b139 · Cited by 12
(2011) · Wiley eBooks · doi:10.1002/9781119950424.ch5 · Cited by 12
ACCORD Glycemia Results Continue to Puzzle
Boyko, E. J. (2010) · Diabetes Care · doi:10.2337/dc10-0432 · Cited by 12
Wang, C., Lin, C., Huang, T.-S., Chien, M.-N., Hsieh, S., Huang, Y., Shih, K., Tu, S., Chang, C., Huang, C., et al. (2012) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2012.05.017 · Cited by 10
Action to Control Cardiovascular Risk in Diabetes (ACCORD) Trial—Clinical Implications
Ismail‐Beigi, F. (2010) · Clinical Chemistry · doi:10.1373/clinchem.2010.148288 · Cited by 11
Controversies for Glucose Control Targets in Type 2 Diabetes: Exposing the Common Ground
Home, P. D. (2019) · Diabetes Care · doi:10.2337/dci19-0002 · Cited by 13
Wang, J., Liu, W.-J., & Lee, W. (2021) · Therapeutic Advances in Chronic Disease · doi:10.1177/20406223211026391 · Cited by 10
Insulin therapy for type 2 diabetes
Meneghini, L. (2012) · Endocrine · doi:10.1007/s12020-012-9817-6 · Cited by 14
Bariatric surgery: An IDF statement for obese Type 2 diabetes
Dixon, J. B., Zimmet, P., Alberti, K. G. M. M., & Rubino, F. (2011) · Obesity Research & Clinical Practice · doi:10.1016/j.orcp.2011.07.002 · Cited by 11
Changing trends in type 2 diabetes mellitus treatment intensification, 2002-2010.
McCoy, R. G., Zhang, Y., Herrin, J. S., Denton, B. T., Mason, J. E., Montori, V. M., Smith, S. A., & Shah, N. D. (2015) · PubMed · Cited by 9
Scheen, A. J. (2018) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2018.10.023 · Cited by 9
Conlin, P. R., Zhang, L., Li, D., Nelson, R. E., Prentice, J. C., & Mohr, D. C. (2023) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2022-003211 · Cited by 11
Rathmann, W., Straßburger, K., Tamayo, T., & Kostev, K. (2011) · Primary care diabetes · doi:10.1016/j.pcd.2011.10.001 · Cited by 9
“[12] M.”
BackgroundCardiovascular Disease in Japanese Patients with Type 2 Diabetes Mellitus
Fujihara, K., & Sone, H. (2018) · Annals of Vascular Diseases · doi:10.3400/avd.ra.17-00109 · Cited by 10
The Role of Bile Acid Sequestrants in the Management of Type 2 Diabetes Mellitus
Ganda, O. P. (2010) · Metabolic Syndrome and Related Disorders · doi:10.1089/met.2010.0095 · Cited by 9
Glycemic Targets in Diabetes Care: Emerging Clarity after Accord.
Buse, J. B. (2015) · Europe PMC (PubMed Central) · Cited by 15
Self-citationCurrie, C. J., Holden, S. E., Jenkins‐Jones, S., Morgan, C. L., Voss, B., Rajpathak, S. N., Alemayehu, B., Peters, J. R., & Engel, S. S. (2017) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13155 · Cited by 9
The current schemes of insulin therapy: Pro and contra
Riddle, M. C. (2021) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2021.108817 · Cited by 15
Self-citationSanz, J., & Fuster, V. (2011) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2011.03.052 · Cited by 10
Charu, V., Liang, J. W., Chertow, G. M., Li, J., Montez‐Rath, M. E., Geldsetzer, P., de Boer, I. H., Tian, L., & Tamura, M. K. (2023) · Journal of the American Society of Nephrology · doi:10.1681/asn.0000000000000272 · Cited by 10
Observational Epidemiology Within Randomized Clinical Trials: Getting a Lot for (Almost) Nothing
Howard, G., & Howard, V. J. (2012) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2011.08.003 · Cited by 8
Intensive glycaemic control in type 2 diabetes mellitus: does it improve cardiovascular outcomes?
Reddy, S. V. B., & Bhatia, E. (2011) · PubMed · Cited by 11
Cardiovascular Importance of Hyperglycemia and Hypoglycemia
Tkáč, I. (2013) · Diabetes Care · doi:10.2337/dcs13-2044 · Cited by 9
Guidelines Versus Guidelines: What's Best for the Patient?
Draznin, B., Nathan, D. M., Korytkowski, M. T., McDonnell, M. E., Golden, S. H., Schutta, M. H., & Cefalu, W. T. (2018) · Annals of Internal Medicine · doi:10.7326/m18-0939 · Cited by 8
Li, Q., Deshan, Y., Zeng, G., Jiang, L., Xu, L., Xu, J., Liu, R., Song, Y., Zhao, X., Hui, R., et al. (2024) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2024.111751 · Cited by 7
Home, P., & Itzhak, B. (2019) · American Journal of Therapeutics · doi:10.1097/mjt.0000000000001077 · Cited by 9
“Intensive use of insulin improved cardiovascular outcomes markedly [risk reduction 42 (9-63)%] as reviewed in the extension phase at 17 years.”
BackgroundCahill, L. E., Warren, R. A., Carew, A. S., Levy, A. P., Ginsberg, H. N., Sapp, J. L., Lache, O., & Rimm, E. B. (2023) · Diabetes Care · doi:10.2337/dc23-0760 · Cited by 8
Sixty years of diabetes management in primary care
Kirby, M. G. (2012) · The British Journal of Diabetes · doi:10.1177/1474651412470393 · Cited by 7
Smith, E. P., & Cohen, R. M. (2015) · Journal of Diabetes Science and Technology · doi:10.1177/1932296815572255 · Cited by 7
“However, despite concerns that aggressive lowering of HbA1c was risky and the increasing awareness that renal disease is associated with artifactual reductions in HbA1c, the excess deaths in ACCORD occurred in those intensively treated whose HbA1c was not low.(37) The operational summary is that CKD and attempts at ti…”
BackgroundSelf-citationNeuropatía diabética y pie diabético
Vázquez, F., Mauricio, D., & Julià, J. V. (2016) · Medicine - Programa de Formación Médica Continuada Acreditado · doi:10.1016/j.med.2016.09.004 · Cited by 19
Anyanwagu, U., Mamza, J., Donnelly, R., & IDRIS, I. R. (2017) · Obesity Research & Clinical Practice · doi:10.1016/j.orcp.2017.08.005 · Cited by 7
Cardiovascular risk in type 2 diabetes patients
Ostroumova, O. D., Васильевна, Г. И., & Михайловна, Ф. В. (2018) · CARDIOVASCULAR THERAPY AND PREVENTION · doi:10.15829/1728-8800-2018-4-81-94 · Cited by 10
“Изучению влияния интенсивной, в сравнении со стандартной, противодиабетической терапии на риск макрососудистых осложнений были посвящены и другие крупные РКИ: ACCORD (Action to Control Cardiovascular Risk in Diabetes) [18], ADVANCE (Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Contr…”
InfluentialEscolar, E., Ujueta, F., Kim, H., Mark, D. B., Boineau, R., Nahin, R. L., Goertz, C., Lee, K. L., Anstrom, K. J., & Lamas, G. A. (2020) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2020.107616 · Cited by 7
McQueen, A., Nordheim, D. V., Caburnay, C. A., Li, L., Herrick, C., Grimes, L. M., Broussard, D. J., Smith, R. E., Lawson, D., Yan, Y., et al. (2024) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph21070936 · Cited by 9
“A change in HbA1c = 0.5% is considered clinically meaningful [44,45], and every 1% reduction is associated with significant risk reduction [46,47].”
BackgroundInfluentialGlucose Control and Cardiovascular Outcomes in Individuals with Diabetes Mellitus
Avitabile, N. A., Banka, A., & Fonseca, V. A. (2012) · Heart Failure Clinics · doi:10.1016/j.hfc.2012.06.009 · Cited by 8
Schwartz, S. S., & Katz, A. (2016) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s65588 · Cited by 8
“Subsequent analysis of the ACCORD data suggested that persistently high A 1C on treatment was associated with an increased risk of mortality in the intensive treatment arm.(24) Severe hypoglycemia was associated with an increased risk of death in both treatment arms.”
Jung, H. H., & Lee, S. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13892 · Cited by 6
“outcome risks increased from an achieved HbA1c level of 42 to 48 mmol/mol, particularly among intensively treated patients.(18,19) In Hazard Ratio (95% CI) Elderly”
BackgroundOrsi, E., Bonora, E., Solini, A., Fondelli, C., Trevisan, R., Vedovato, M., Cavalot, F. L., Zerbini, G., Morano, S., Nicolucci, A., et al. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9010246 · Cited by 6
“0% and when little or no decrease in HbA1c followed treatment initiation [12].”
BackgroundResultCassidy, F. C., Lafferty, S., & Coleman, C. M. (2021) · IntechOpen eBooks · doi:10.5772/intechopen.94271 · Cited by 6
Aragón‐Sánchez, J., Víquez‐Molina, G., López‐Valverde, M. E., Rojas‐Bonilla, J. M., & Murillo‐Vargas, C. (2021) · Advances in Wound Care · doi:10.1089/wound.2021.0072 · Cited by 6
Awdishu, L., Moore, T., Morrison, M., Turner, C., & Trzebinska, D. (2019) · Pharmacy · doi:10.3390/pharmacy7030083 · Cited by 9
Arrhythmogenic effects of hypoglycemia
Лаптев, Д. Н., & Шмушкович, И. А. (2012) · Diabetes Mellitus · doi:10.14341/2072-0351-5975 · Cited by 8
Intensified glucose lowering in type 2 diabetes: time for a bolder reappraisal
Czupryniak, L., Szymańska‐Garbacz, E., Pawłowski, M., Saryusz‐Wolska, M., & Loba, J. (2010) · Diabetologia · doi:10.1007/s00125-010-2011-6 · Cited by 6
“5% [2], but the recently published analysis [4] shows that the increase in the mortality rate was largely seen only in those who failed to achieve the target levels of 6.”
BackgroundBloomgarden, Z. T., EINHORN, D. F., Handelsman, Y., Misra, A., Zonszein, J., Grunberger, G., Jellinger, P. S., & Garber, A. J. (2018) · Journal of Diabetes · doi:10.1111/1753-0407.12668 · Cited by 6
Prevalence and Risk Factors of Stroke in Inpatients with Type 2 Diabetes Mellitus in China
Xie, Z., Wang, C., Huang, X., Wang, Z., Shangguan, H., & Wang, S.-H. (2024) · Current Medical Science · doi:10.1007/s11596-024-2911-1 · Cited by 6
Optimal Glycemic Control in the Elderly: Where is the Evidence and Who Should Be Targeted?
Tessier, D. (2011) · Aging Health · doi:10.2217/ahe.10.86 · Cited by 5
Meguro, S., Sano, M., Kawai, T., Matsuhashi, T., Mogi, S., Fukuda, K., Itoh, H., & Suzuki, Y. (2012) · Endocrine Research · doi:10.3109/07435800.2012.662664 · Cited by 5
“However, detailed analysis could not identify the reasons for failure of the ACCORD study to show improvement ofmortality, and it was indicated that better glycemic control might lead to a better cardiovascular outcome (6).”
BackgroundThuesen, A. C. B., & Vaag, A. A. (2018) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13238 · Cited by 5
Prevencija dijabetesne nefropatije
Djukanović, L. (2012) · Биомедицинска истраживања · doi:10.7251/bii1202067d · Cited by 5
Cardiovascular Outcomes Trials of Glucose-Lowering Drugs or Strategies in Type 2 Diabetes
Gerstein, H. C., & Shah, R. (2017) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2017.10.003 · Cited by 6
Feldbrin, Z., Shargorodsky, M., Wainstein, J., Melnikov, D., & Zandman‐Goddard, G. (2018) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2018.01.013 · Cited by 5
Management of Diabetes Mellitus
Jenkins, A. J., SCOTT, E. S., Fulcher, J., Kilov, G., & Januszewski, A. S. (2018) · Contemporary cardiology · doi:10.1007/978-3-319-97622-8_7 · Cited by 6
A new perspective on lowering CV risk from hypoglycaemia
Solis‐Herrera, C., Sheikh, O., & CHILTON, R. J. (2019) · European Heart Journal · doi:10.1093/eurheartj/ehz730 · Cited by 5
Cardiovascular outcome trials in type 2 diabetes: A nurse practitioner perspective
Kruger, D. F. (2018) · Journal of the American Association of Nurse Practitioners · doi:10.1097/jxx.0000000000000126 · Cited by 4
“…hoc analyses of ACCORD suggested that excess mortality in the intensive therapy group was most apparent in the subgroup of subjects whose high HbA1c levels persisted during the first 12 months of follow-up despite use of intensive therapeutic strategies (Miller et al., 2014; Riddle et al., 2010).”
BackgroundSmetana, G. W., Nathan, D. M., Dugdale, D. C., & Burns, R. B. (2019) · Annals of Internal Medicine · doi:10.7326/m19-0946 · Cited by 8
Wang, J.-M., Miao, M.-Y., Jia, Y., Wang, X., Wu, X., Wan, Z., Zheng, Y., Qin, L., Li, F., & Chen, G. (2024) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2024.111100 · Cited by 7
Chu, F., Yan, H., Lei, K., Li, D., Dong, S., Zhang, Y., Cheng, Y., Li, Z., Li, Z., Qian, H., et al. (2025) · International Journal of Cardiology · doi:10.1016/j.ijcard.2025.133184 · Cited by 4
Glycemic control and outcomes in people with diabetes and CKD
Zoungas, S., & Chalmers, J. P. (2012) · Nature Reviews Nephrology · doi:10.1038/nrneph.2012.18 · Cited by 4
“A nonlinear relationship between HbA 1c levels and mortality has recently been reported by a number of other studies of people with diabetes”
BackgroundZhao, X., Kang, Y., Wang, X., Yang, X., Ai, G., Liu, Y., Pei, X., Zhang, J., Gu, C., Zhang, Y., et al. (2020) · Herz · doi:10.1007/s00059-020-04999-9 · Cited by 4
Sociodemographic and clinical predictors of refractory type 2 diabetes patients
Alharbi, T., Tourkmani, A. M., Rsheed, A. M. B., Alabood, A., & Alotaibi, Y. K. (2021) · Saudi Medical Journal · doi:10.15537/smj.2021.2.25694 · Cited by 4
Treatment of diabetes mellitus has borne much fruit in the prevention of cardiovascular disease
Yagyu, H., & Shimano, H. (2022) · Journal of Diabetes Investigation · doi:10.1111/jdi.13859 · Cited by 4
Noguchi, K., Sakakibara, M., Asakawa, N., Tokuda, Y., Kamiya, K., Yoshitani, T., Oba, K., Miyauchi, K., Nishizaki, Y., Ogawa, H., et al. (2016) · Circulation Journal · doi:10.1253/circj.cj-15-1126 · Cited by 5
Metadata
- Authors
- Riddle, M. C., Ambrosius, W. T., Brillon, D. J., Buse, J. B., Byington, R. P., Cohen, R. M., Goff, D. C., Malozowski, S., Margolis, K. L., Probstfield, J. L., Schnall, A., Seaquist, E. R., & for the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Investigators
- Affiliations
- Oregon Health & Science University (US)
- Wake Forest University Health Sciences (US)
- Cornell University (US)
- University of North Carolina at Chapel Hill (US)
- University of Cincinnati (US)
- National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, Maryland;
- HealthPartners (US)
- University of Washington (US)
- Case Western Reserve University (US)
- University of Minnesota (US)
- Corresponding author
- Riddle, Matthew C.
- ORCID
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2010-05-01
- Volume
- 33
- Issue
- 5
- Pages
- 983-990
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- PMC
- PMC2858202
- OpenAlex
- W2078241682
- Cited by
- 406
- References
- 21
- Citations by year
- 2026: 2 · 2025: 4 · 2024: 9 · 2023: 12 · 2022: 13 · 2021: 13 · 2020: 18 · 2019: 25 · 2018: 26 · 2017: 31 · 2016: 27 · 2015: 37 · 2014: 28 · 2013: 30 · 2012: 40
- FWCI
- 38.36
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Diabetes Care (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Carolina Digital Repository (University of North Carolina at Chapel Hill) (submittedVersion)
- UNC Libraries
- Funders
- National Institutes of Health (n01hc95183-23-0-0, n01hc95180-24-0-1, n01hc95184-24-0-1, n01hc95181-23-0-1, n01hc95182-23-0-1, n01hc95178-28-0-1, n01hc95179-25-0-0)
- National Heart, Lung, and Blood Institute (N01- HC-95181, N01 HC095184, N01-HC- 95180, N01-HC-95178, N01 HC095182, N01 HC095181, Y01 HC001010, N01-HC-095183, N01 HC095178, N01-HC-95184, N01HC95179, IAAY1-HC-1010, IAA #Y1-HC-9035, N01 HC095180, Y01 HC009035, N01‐HC‐95183, N01-HC-95182, N01 HC095179)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- HbA1c, all-cause mortality, tight glycemic control, type 2 diabetes, ACCORD trial, mortality risk
- MeSH terms
- Aged, Cause of Death, Diabetes Mellitus, Type 2, Female, Follow-Up Studies, Glycated Hemoglobin, Humans, Hyperglycemia, Hypoglycemic Agents, Male, Middle Aged, Risk Factors, Multivariate Analysis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.